None
Conditions
Interventions
Experimental group:Jijianneng Yuehuo Oral Solid Beverage
Sponsors
Shanghai Fengxian District Central Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Ages 40 to 65 (inclusive); 2.Body Mass Index (BMI) is between 18.5 (inclusive) and 30 kg/m²; 3.Maintain a stable diet and lifestyle habits throughout the entire trial period; 4.Can read Chinese and accurately understand the test process, voluntarily participated in the test and signed the informed consent form for the research.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women, or those planning to become pregnant within 6 months after the trial. 2.Patients with severe diseases of the heart, liver, kidney, and hematopoietic system were combined. 3.Serious mental illness or cognitive impairment, unable to make independent decisions. 4.Long-term individuals who engage in high-intensity regular exercise, including: continuous participation for>=6 months, >=3 times per week, regularly participating in aerobic exercises (such as running, swimming, cycling), high-intensity interval training (HIIT), or resistance training, with each training session lasting >=30 minutes. 5.Individuals who have used any tobacco products or abused alcohol (men >40 g ethanol/day, women >20 g ethanol/day) within the past 6 months. 6.Long-term specific dietary pattern individuals (duration>=6 months), including but not limited to: vegetarians (excluding all animal-derived foods), Mediterranean diet followers, ketogenic diet followers, etc. 7.Taking medications, health products, or functional foods (including pyrroloquinoline quinone, astaxanthin, ergothioneine, S-adenosylmethionine, and sulforaphane) within two weeks that are related to the subject's functions, which may affect the judgment of the results. 8.Subjects who have participated in other drug clinical trials within the past 1 month prior to enrollment. 9.Known or suspected allergy to the investigational drug ingredients. 10.Other clinical assessments deemed unsuitable for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of leukocyte telomere length (relative length); | — |
Secondary
| Measure | Time frame |
|---|---|
| General clinical symptom assessment: mental status, sleep, diet, urination and defecation;;Profile of Mood States (POMS) Score;Aging Gene Test: SIRT1, mTOR Gene Expression Level , PBMCs (Peripheral Blood Mononuclear Cells);Fatigue Scale-14 Score (FS-14);Lymphocyte subsets (na?ve CD4+ and CD8+ T cells, memory CD4+ or CD8+ T cells);Blood routine;Fatigue Severity ;Vital signs: Body temperature (ear temperature), pulse, systolic blood pressure, diastolic blood pressure; | — |
Countries
China
Contacts
Public ContactZhu Haiying
Shanghai Fengxian District Central Hospital
Outcome results
None listed